Cell · 2026
Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reyes José, Del Priore Isabella, Chaikovsky Andrea C, Pasnuri Nikhita, Elhossiny Ahmed M, Park Jin, Weiler Philipp, Krause Tobias, Moorman Andrew, Snopkowski Catherine, Takizawa Meril, Burdziak Cassandra, Ratnayeke Nalin, Masilionis Ignas, Ho Yu-Jui, Chaligné Ronan, Romesser Paul B, Filliol Aveline, Nawy Tal, Morris John P, Zhao Zhen, Pasca Di Magliano Marina, Alonso-Curbelo Direna, Pe'er Dana, Lowe Scott W
Аннотация
The benign-to-malignant transition is a defining step in cancer progression. To investigate when and how malignancy initiation occurs and tissue reorganization proceeds, we combine single-cell and spatial transcriptomic profiling in mouse models of pancreatic ductal adenocarcinoma (PDAC) that capture spontaneous p53 loss. Among Kras-mutant cells, we find that oncogenic and tumor-suppressive programs, including those controlled by p53, CDKN2A, and SMAD4, are co-activated in a discrete progenitor-like population, engaging senescence-like responses. Using a framework we developed for spatial analysis, we show that a niche centered on these cells undergoes stepwise remodeling during tumor progression, mirroring invasive PDAC. Transient KRAS inhibition depletes progenitor-like cells and dismantles their niche, delaying malignancy initiation. Conversely, p53 suppression enables progenitor cell expansion, epithelial-mesenchymal reprogramming, and immune-privileged niche formation. These findings position the progenitor-like state at the convergence of cancer-driving mutations, plasticity, and tissue remodeling, revealing a critical window for intercepting malignancy.